Aktis Oncology, Inc. · NASDAQ:AKTS
Aktis Oncology — Investor Presentation (September 2026)
26 slides from Aktis Oncology's investor presentation, September 2026
Slide 1: Maximizing the Impact of Radiopharmaceuticals
Maximizing the Impact of Radiopharmaceuticals September 2026 1
Slide 2: Disclaimer
Disclaimer Information in this presentation and the accompanying oral presentation contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 that involve substantial risks and uncertainties about Aktis Oncology and the industry in which Aktis Oncology op
Slide 3: Aktis Oncology has built the core elements for leadership in targeted radiopharmaceuticals
Aktis Oncology has built the core elements for leadership in targeted radiopharmaceuticals OUR VISION To expand targeted radiopharmaceuticals to large patient populations INNOVATION ENGINE SUPPLY CHAIN Multi-asset pipeline driven by Patient-centric novel miniprotein end-to-end manufacturing radiocon
Slide 4: Aktis is focused on executing with quality and speed
Aktis is focused on executing with quality and speed Strong execution in 2026 is building momentum for 2027 AKY-1189 (Nectin-4) AKY-2519 (B7-H3) Corporate 2026 1Q’26: Granted Fast Track 1Q’26: Received IND clearance 2H’26: Aktis GMP designation in locally manufacturing suite advanced or mUC 2Q’26: m
Slide 5: Targeted radiopharmaceuticals have a unique potential to transform the patient journey
Targeted radiopharmaceuticals have a unique potential to transform the patient journey Cell-kill mechanism orthogonal to existing systemic modalities A critically needed new therapeutic option to Non-overlapping acquired radiopharmaceuticals resistance with deliver broad and meaningful patient impac
Slide 6: Targeted radiopharmaceuticals are poised to be a large new category in cancer care
Targeted radiopharmaceuticals are poised to be a large new category in cancer care Total addressable market projections for radiopharmaceuticals Radiopharmaceuticals PRE-2030 POST-2030 projected to mirror growth of ADC market ~ 25 – 35+ TAM ($B) Note: ~$35B in 2030 for ADCs Keys to unlocking the pot
Slide 7: Aktis' novel miniprotein radioconjugate platform is designed to unlock the full potential of radiopharmaceuticals
Aktis’ novel miniprotein radioconjugate platform is designed to unlock the full potential of radiopharmaceuticals… Expanding impact with miniproteins High tumor Fast clearance Broad universe Prioritizing penetration and high-affinity, to optimize therapeutic index of addressable targets actinium-225
Slide 8: A resilient and scalable supply chain designed for seamless delivery and dosing
…with a resilient and scalable supply chain designed for seamless delivery and dosing DRUG PRODUCT MANUFACTURE MINIPROTEIN MANUFACTURING Stockpiled miniprotein precursor sourced from multiple partners Assembly of Quality Unit dose drug product control release PATIENT ADMINISTRATION ISOTOPE SUPPLY Mu
Slide 9: We are advancing a novel pipeline with broad patient impact
We are advancing a novel pipeline with broad patient impact PROGRAM TARGET/INDICATION DISCOVERY IND-ENABLING PHASE 1b PHASE 2/3 UPCOMING MILESTONES mUC and other Nectin-4 Ph1b ongoing AKY-1189 expressing Fast Track Designation* Prelim data in 1Q’27 solid tumors B7-H3 expressing Ph1b ongoing mCRPC Pr
Slide 10: We have an accomplished leadership team and premier scientific advisors
We have an accomplished leadership team and premier scientific advisors Senior leadership team played leading roles in 14 FDA product approvals Matthew Roden, PhD Akos Czibere, MD PhD Kyle Kuvalanka, MBA President & CEO Chief Medical Officer Chief Financial Officer Ken Herrmann, MD Chair, Aktis SAB
Slide 11: AKY-1189
AKY-1189 Miniprotein Radioconjugate Targeting Nectin-4
Slide 12: Broad Nectin-4 expression across multiple solid tumors supports potential blockbuster opportunity
AKY-1189 Broad Nectin-4 expression across multiple solid tumors supports potential blockbuster opportunity US treated metastatic 2L+ NECTIN-4 Indication patients2 Nectin-4+3 Urothelial cancer 9K 90% • Clinically and commercially Breast cancer4 56K 83% validated target • Highly expressed in multiple
Slide 13: Nectin-4 clinical validation supports a significant market opportunity in urothelial cancer
AKY-1189 Nectin-4 clinical validation supports a significant market opportunity for AKY-1189 in urothelial cancer ~18k US treated metastatic urothelial $7 PADCEV® forecasted PATIENTS cancer (mUC) patients1 BILLION worldwide peak sales2 Current mUC standard of care AKY-1189 potential 1st Indication L
Slide 14: Clinical imaging demonstrates robust tumor uptake and retention of AKY-1189
AKY-1189 Clinical imaging demonstrates robust tumor uptake and retention of AKY-1189, supporting a wide therapeutic window Favorable normal tissue uptake compared to approved RLTs* Rapidly cleared from kidney and bone marrow Predicted absorbed Kidneys AKY-11891 Pluvicto 2 Lutathera®3 Bone Marrow dos
Slide 15: Robust tumor uptake observed in urothelial cancer and beyond
AKY-1189 Robust tumor uptake observed in urothelial cancer and beyond Urothelial cancer ER/PR+ mBC Triple negative breast cancer Colorectal cancer 60 min 60 min 60 min 60 min [68Ga]Ga-AKY-1189 PET/CT • Robust tumor uptake observed in high unmet need tumor types with SUVmax 20-40 • Consistent normal
Slide 16: Phase-1b trial actively enrolling patients across mUC and other Nectin-4 expressing tumors
AKY-1189 Phase-1b trial actively enrolling patients across mUC and other Nectin-4 expressing tumors NECTINIUM-2 Trial design PART 1 PART 2 Dose escalation BOIN, mUC + Nectin-4+ patients Dose expansion, multiple tumor types (n=~30 + backfill) (n=30-40 per cohort) Expansion cohorts 12 MBq THERAPY Coho
Slide 17: AKY-2519
AKY-2519 Miniprotein Radioconjugate Targeting B7-H3
Slide 18: Broad B7-H3 expression across multiple solid tumors supports potential blockbuster opportunity
AKY-2519 Broad B7-H3 expression across multiple solid tumors supports potential blockbuster opportunity US treated metastatic 2L+ B7-H3 Indication patients1 B7-H3+2 Prostate cancer 20K 81% • Clinically validated target • Highly expressed in multiple NSCLC 54K 70% solid tumors SCLC 12K 65% • Minimal
Slide 19: Significant market opportunity for AKY-2519 in prostate cancer
AKY-2519 The success of first-generation radiopharmaceuticals supports a significant market opportunity for AKY-2519 in prostate cancer ~39k US treated mCRPC $5 PLUVICTO® forecasted PATIENTS patients1 BILLION worldwide peak sales2 Current mCRPC standard of care AKY-2519 potential 1L 2L 3L Lead in 3L
Slide 20: AKY-2519 demonstrates robust tumor uptake and retention with wide therapeutic index
AKY-2519 AKY-2519 demonstrates robust tumor uptake and retention with predicted absorbed doses suggesting a wide therapeutic index A PET/CT B SPECT/CT E % COVERAGE F Mean Absorbed Dose Predicted Dose1 SECT/CT AXIAL IMAGES AT 24 HOURS Region of Interest Coefficient (225Ac) at 8 MBq x 4 GyRBE=5/MBq Gy
Slide 21: Clinical imaging and dosimetry data in patients with mCRPC
AKY-2519 Clinical imaging and dosimetry data in patients with mCRPC suggest a wide therapeutic index and informed the Phase 1b trial design Normal tissue doses were below Robust tumor uptake and retention with predicted absorbed established clinical benchmarks doses suggesting a wide therapeutic ind
Slide 22: mCRPC-dedicated Phase 1b trial actively enrolling patients
AKY-2519 mCRPC-dedicated Phase 1b trial actively enrolling PLUVICTO- naïve and -experienced patients BActinium-1 Trial design Dose escalation: BOIN Backfill (n ≈ 30/cohort; escalation pts included) 12 MBq THERAPY THERAPY Backfill Dose 1 PLUVICTO-naïve [225Ac]Ac-AKY-2519 [225Ac]Ac-AKY-2519 9 MBq Coho
Slide 23: [68Ga]Ga-AKY-2519 demonstrates robust tumor uptake in a variety of solid tumors
[68Ga]Ga-AKY-2519 demonstrates robust tumor uptake AKY-2519 in a variety of solid tumors Representative patients across solid tumor types with robust tumor uptake at 120 minutes following [68Ga]Ga-AKY-2519 administration • Uptake of [68Ga]Ga-AKY- 2519 was observed across multiple tumor types at vari
Slide 24: On track to initiate Phase 1b AKY-2519 basket trial in 2H'26
AKY-2519 On track to initiate Phase 1b AKY-2519 basket trial in 2H’26 BActinium-2 Trial design PART 1 PART 2 Dose escalation: BOIN (n = up to 21) Backfill (n = up to 60) Dose expansion (n = up to 71) 12 MBq BACKFILL 2L(+) NSCLC THERAPY Cohort 1 Dose 1 [225Ac]Ac-AKY-2519 2L(+) NSCLC THERAPY 2L(+) Oth
Slide 25: Aktis is positioned to lead the next generation of targeted radiopharmaceuticals
Aktis is positioned to lead the next generation of targeted radiopharmaceuticals Novel and Differentiated Platform Two Clinical Programs Accomplished Addressing Large Market Leadership Team Tumor Types Strong Imaging Proof-of- Balance Sheet Concept in Patients Isotope Supply Pipeline of Potential fr
Slide 26: Thank You
Thank You
Aktis Oncology — Investor Presentation (September 2026) on 6ix